anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The results of several large randomized controlled trials (RCTs) have changed the clinical practice of bariatric surgery. However, the characteristics of global RCTs of bariatric surgery have not been reported internationally and whether there was research waste in these RCTs is unknown.
METHODS: Search ClinicalTrials.gov for bariatric surgery RCTs registered between January 2000 and December 2022 with the keywords 'Roux-en-Y gastric-bypass' and 'Sleeve Gastrectomy'. The above analysis was conducted in January 2023.
RESULTS: A total of 326 RCTs were included in this study. The number of RCTs registered for sleeve gastrectomy and gastric bypass surgery increased year by year globally. Europe has always accounted for the largest proportion, Asia has gradually increased, and North America has decreased. A total of 171 RCTs were included in the analysis of waste, of which 74 (43.8%) were published. Of the 74 published RCTs, 37 (37/74, 50.0%) were judged to be adequately reported and 36 (36/74, 48.6%) were judged to have avoidable design defects. In the end, 143 RCTs (143/171, 83.6%) had at least one research waste. Body weight change as the primary endpoint (OR: 0.266, 95% CI: 0.103-0.687, P =0.006) and enrolment greater than 100 (OR: 0.349, 95% CI: 0.146-0.832, P =0.018) were independent protective factors for research waste.
CONCLUSIONS: This study for the first time describes the characteristic changes of the mainstream RCT of bariatric surgery globally in the last 20 years and identifies a high research waste burden and predictive factor in this area, which provides reference evidence for carrying out bariatric surgery RCTs more rationally.
The invention relates to the technical field of liposome medicaments, and relates to an artesunate liposome as well as preparation and application thereof. The artesunate liposome comprises the artesunate, phospholipid, cholesterol and PEGylated phospholipid. Wherein the mass ratio of the phospholipid to the cholesterol to the PEG phospholipid is (1-30): (0.2-10): (0 to 20). The medicine-to-lipid ratio of the artesunate to the phospholipid is 1: 5-1: 20(m/m), and the mass ratio of the phospholipid to the cholesterol is 2: 1-5: 1. the drug-loaded liposome is prepared by a solvent-assisted calcium acetate gradient method. The invention utilizes the solvent-assisted active drug-loading technology, which not only solves the limitation that the insoluble drug can not be actively loaded; secondly, the problems of low solubility, unstable structure and short half-life period in vivo of the artesunate can be solved; and the anti-tumor effect of the artesunate can be obviously improved. The liposome has high encapsulation efficiency, uniform particle size and good stability.
PURPOSE:To provide an inexpensive water-soluble thickener which exhibits a high thickening effect at a low concentration, consisting of a copolymer having a fine particle size produced from a polysaccharide, a water-soluble ethylenically unsaturated monomer and a crosslinking agent. CONSTITUTION:A polysaccharide (A) (such as natural starch, alpha-starch, dextrin, oxidized starch, natrual cellulose or alkali cellulose), a water-soluble ethylenically unsaturated monomer (B) (e.g. sodium methacrylate or triethanolamine salt of acrylic acid) and a crosslinking agent (C) (e.g. methylenebisacrylamide) are reacted together in a weight ratio of A:B:C=100:10-2,000:0.0001-20. Then the resulting copolymer is crushed to a size of 149mu or below in order to obtain the desired thickener. The viscosity of a 1% aq. soln. thereof is 4,000cps or above.
Human infections caused by Pseudomonas citronellolis, an environmental bacterium, are infrequent, with only two cases related to uncommon urinary tract infections and bacteremia reported in recent years. All these cases typically occurred in elderly patients with compromised or decreased immune function. Simultaneously, the epithelial barrier disruption induced by invasive biopsy procedures or gastrointestinal disorders such as gastroenteritis provided a pathway for Pseudomonas citronellolis to infiltrate the organism. In this study, we present the first report of a case where Pseudomonas citronellolis and Escherichia coli were isolated from the inflamed appendix of a patient without underlying conditions. Compared to the Escherichia coli, Pseudomonas citronellolis has never been isolated in patients with appendicitis. We identified the species using MALDI-TOF MS and genetic sequencing. Based on our findings, we highlight the perspective that Pseudomonas citronellolis can colonize the intestines of healthy individuals and may trigger infections like appendicitis.
Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.
Life time risk of developing breast cancer is greatly elevated in women with familial breast cancer, especially in BRCA carriers. Prevention and early detection strategies in these high risk women include risk reducing surgery, chemoprevention and close surveillance with semiannual clinical breast exams and yearly mammograms starting at age 25-35. Unfortunately, screening mammography detects only half the breast cancers in mutation carriers, presumably due to higher breast density in the younger women and perhaps due to inherent characteristics of their tumors such as rapid growth. In light of these limitations in this high risk group, some have suggested incorporation of semiannual mammograms and/or other imaging modalities such as ultrasound (US) and MRI.

In this study, high risk women who have a suspicious mammographic lesion - categorized as Breast Imaging Reporting and data System (BI-RADS) 4 will be recruited to undergo a breast MRI before to a biopsy of the suspicious abnormality. All women will undergo a biopsy as a part of her standard of care. The results of the MRI will not influence our decision on whether a biopsy should be performed. The MRI results will be compared with the biopsy results with pathology as the gold standard.
The invention relates to a solid-phase cancer target affinity column, a preparation and screening method and an active component. The solid phase cancer target is used for screening latent anti-cancer active component in crude drug. The cancer target is VEGF165 protein or basic fibroblast growth factor. The affinity column is an agarose gel affinity column. The method for preparing the solid phase cancer target affinity column comprises the following steps: packing agarose gel and flushing; adding a solution containing the cancer target in the gel column, staying the solid phase overnight to prepare the affinity column; removing the cancer target solution after solid phase, sealing the affinity column, and washing the affinity column. The solid phase VEGF165 agarose gel is capable of screening latent anti-cancer effective component from the crude drug, and the latent anti-cancer effective component interacts with VEGF165. The method is suitable for using other targeting molecules to screen the efficacy component of the crude drug. The method saves time and fund for screening anticancer active ingredients from the crude drug.
The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suitable cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells.
The invention discloses an external-use liniment for treating scald. The external-use liniment comprises the following raw materials (by weight): 15-20 parts of sophora flavescens, 10-15 parts of cooked rhubarb, 4-6 parts of polygonum cuspidatum, 2-4 parts of scutellaria baicalensis, 5-7 parts of paulownia skin, 6-10 parts of girald pteroxygonum root, 8-10 parts of typhae pollen, 2-4 parts of paris polyphylla, 4-6 parts of cottonrose hibiscus, 2-4 parts of pericarpium arecae, 5-6 parts of bletilla striata, 7-8 parts of rhizoma corydalis, 6-10 parts of nidus vespae, 2-4 parts of calcined fossil fragment, 4-6 parts of Sida acuta Burm. F, 3-5 parts of radix angelicae, 2-4 parts of ligustrum leaf, 5-6 parts of ligusticum wallichii, 6-8 parts of prepared olibanum, 2-4 parts of Cipadessa cinerascens (Pell.) Hand.-Mazz. and 1-3 parts of Viburnum lutescens Bl. The external-use liniment is prepared from pure traditional Chinese medicines, has a scientific formula, and has efficacy of clearing away heat and toxic materials, cooling blood and stopping bleeding, eliminating swelling and stopping pain, and sterilizing and diminishing inflammation. The drug can rapidly heal wounds fundamentally and has characteristics of fast pain relief, quick drying of wounds, short course of treatment, strong anti-inflammatory effect and the like. After scald is healed, hyperplasia or escharosis will be avoided, and scars will be prevented.
BACKGROUND: Knowledge of mental disorders among patients with persistent opioid use for the treatment of chronic non-cancer pain is essential, as mental disorders and symptoms can exacerbate or perpetuate pain and impact on the ability of patients to manage their illness. We have studied the prevalence of mental disorders and symptoms, including substance use disorders, in patients with persistent opioid use in 2019.
MATERIAL AND METHOD: Persons ≥ 18 years with persistent opioid use and persons ≥ 18 years with at least one registered mental disorder in the specialist healthcare service in 2019 were included. Data were retrieved from national health registries in Norway. Patients who received opioids reimbursed for the treatment of chronic pain were compared with those who received opioids without reimbursement.
RESULTS: The prevalence of mental disorders and symptoms was 34 % among 14 403 persons who received reimbursed opioids, and 42 % among 38 001 persons who received opioids without reimbursement. This is equivalent to a two to threefold increase in prevalence compared to the general population. There was a particularly higher prevalence of anxiety disorders and substance use disorders. The prevalence of mental disorders and symptoms was highest in the age group 18-44 years (49-55 %).
INTERPRETATION: Among patients with persistent opioid use, a large proportion had mental disorders and symptoms, which are known risk factors for developing problematic opioid use and opioid use disorder.
Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
The present invention relates to novel pluripotent embryonic cell populations derived from embryonic stem cell populations and methods to produce such pluripotent embryonic cell populations. Disclosed is an embryonic stem cell-derived pluripotent embryoid body cell population having one or more cells capable of developing into cells of hematopoietic and/or endothelial lineage. Also disclosed is an embryoid body cell population-derived mixed population of endothelial and erythroid cells. Also disclosed is an embryoid body cell population-derived embryonic blast cell population capable of developing into a variety of hematopoietic cell types. The invention is additionally directed to embryonic stem cell population-derived T and B cell populations. Methods to identify embryonic cell compounds are also disclosed for therapeutic and experimental use.
Ribavirin is a synthetic nucleoside analogue (purine analogue). The chemical name of ribavirin is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide and has the following structural formula (see Figure 1).

Figure 1: Structural Formula

Ribavirin, USP is a white, crystalline powder. It is freely soluble in water and slightly soluble in dehydrated alcohol. The molecular formula is C8H12N4O5 and the molecular weight is 244.21.

Each ribavirin capsule, USP intended for oral administration contains 200 mg of ribavirin, USP in white, hard gelatin capsule shells. In addition, each capsule contains the following inactive ingredients: crospovidone, magnesium stearate, microcrystalline cellulose, povidone, and silicon dioxide. The capsule shell consists of gelatin and titanium dioxide. It may also contain sodium lauryl sulfate. The capsule is printed with black pharmaceutical ink.
A process is provided to improve the insulin sensitivity and glucose tolerance of an individual's metabolism. The process includes providing at a first location at least one polyol in an aqueous solution. A minor effective amount of a water soluble mineral composition comprising chromium picolinate is admixed with the aqueous solution to produce an aqueous polyol-chromium composition. The composition is dried and processed to produce solid chromium-infused polyol particles. The particles are packaged and transported to a second location. A selected quantity of the chromium-infused polyol particles are used to produce a food product selected from a group consisting of a liquid food including a liquid and at least fifty percent solids by weight, and a solid food composition. The food products produced with the mineral-infused polyol particles are packaged. The packaged food products are sold to the individual. The individual ingests the food product containing the mineral-infused polyol.
The present invention relates to the application of drynaria to the treatment of hyperthyroidism and a preparation. Traditional Chinese medicine drynaria is applied to the treatment of the hyperthyroidism, and administration is carried out in the administration form of oral administration or injection, etc. The present invention is used for treating hyperthyroidism and has the advantages of simple formula, obvious therapeutic effect, simple and convenient preparation technique and low cost of production and use. Particularly, a Chinese medicine preparation has no toxic side effect and can be widely accepted by a doctor and a patient. When a combined antithyroid drug of the product is applied, the dosage of the antithyroid drug can be reduced, and the incidence rate of adverse reactions of leukocyte descent, rash, etc. is lowered.
Some embodiments provide a chewing or bubble gum composition which includes a liquid fill composition and a gum region which surrounds the liquid fill. The gum region has at least two layers in which the gum layer adjacent to the liquid fill includes maltitol. More specifically, in some embodiments, the gum region includes at least a first layer and a second layer. The first layer of the gum region is adjacent to the liquid fill and includes maltitol. In some embodiments, for instance, maltitol may be present in amounts of about 30% to about 80% by weight of the first layer. The second layer of the gum region at least partially surrounds the first layer. The composition may also include a coating region which surrounds the gum region.
Functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin and including cerebral ischemia and stroke is enhanced by administration of a composition comprising a therapeutically effective amount of a natural protein mixture derived from bone, cartilage and/or tendon/ligament tissue and having bone morphogenic and/or osteoinductive characteristics. This natural protein mixture is preferably the mixture known as BP (Bome Protein) which mixture is derived from bovine bone material by extracting proteins from demineralized bone particles and purifying the extract by ultrafiltration, anion exchange, cation exchange and reverse phase high resolution liquid chromatography. In the rat model it is shown that the enhancement regarding BP-treated animals compared with sham-treated animals includes acceleration of recovery for reversible and irreversible cases of spinal cord lesions and a higher recovery level, i.e. a smaller irreversible functional loss for irreversible cases. Recovery is believed to be due to the beneficial effect of the natural protein mixture on cell survival after injury, on cell protection against exitotoxicity (e.g. glutamate intoxication) as well as on injury site conditions favoring axon regeneration. Compared with known administration of single species of recombinantly produced bone morphogenic proteins for similar aims, the natural protein mixture is effective in considerably lower doses.
Systems and methods for a microfluidic biosensor patch and health monitoring system may include an iontophoresis module, a multi-inlet microfluidic sweat collection and sampling module, and a molecularly imprinted polymer (MIP) organic compound sensor module. An iontophoresis module may provide for stimulation of a biofluid sample. A biofluid may be a sweat sample. Stimulation may be achieved via electrostimulation and/or application of a stimulating agent. A microfluidic sweat collection and sample module may include several adhesive layers with carefully designed inlets, channels, a reservoir, and an outlet for the efficient collection and sampling of biofluid. A MIP sensor module may quickly and accurately identify concentrations of key metabolites present in a biofluid sample which may indicate certain health conditions.
PURPOSE: A peptide derived from GnRH for the immunocastration of mammals is used in the field of Genetic Engineering and Biotechnology. CONSTITUTION: A peptide derived from GnRH for the immunocastration of mammals is provided. Vaccinations tests have been carried out in mammals with the gonadotropin release hormone (GnRH), in order to ellicit and immune response which neutralizes to activity of said hormone. Also, provided is the use of a GnRH variant of mammals wherein a glycine residue has been substituted by a prolin residue in position 6: Glu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly. This substitution or change has induced an immune response which is superior than that of natural GnRH, when both are coupled to a same carrier protein, in experiments carried out in pigs. This same result can be expected in any other mammal since this hormone is present in all species.
Dorzolamide hydrochloride and timolol maleate ophthalmic solution, USP (preservative free) is supplied in a foil pouch containing 5 low density polyethylene 0.2 mL single-use containers.

Carton of 12 pouches NDC 50742-323-60, package of 60 single-use vials.

Store dorzolamide hydrochloride and timolol maleate ophthalmic solution, USP (preservative free) at 20° to 25°C (68° to 77°F) [See USP controlled room temperature]. Do not freeze.

Store in the original pouch. After the pouch is opened, store the remaining single-use containers in the foil pouch to protect from light. Write down the date you open the foil pouch in the space provided on the pouch. Discard any unused containers 15 days after first opening the pouch.
PURPOSE: A composition for treating and preventing allergic inflammatory diseases which contains red ginseng extract is provided to enhance elimination performance of DPPH-free radical, superoxide anion, and hydrogen peroxide. CONSTITUTION: A composition for treating and preventing allergic inflammatory diseases contains red ginseng extract as active ingredient. The red ginseng is obtained by the following steps: primary natural drying of 3-8 year old ginseng at 10-60 deg. Celsius for 1-24 hours; drying the same for the second time to remove moisture only after washing the natural dried ginseng; primary steaming the dried ginseng at 60-120 deg. Celsius for 1-48 hours; and during the ginseng at 30-80 deg. Celsius for 1-72 hours. The extract of red ginseng is extract which is used in water, methanol, ethanol, butanol or a mixed solvent.
Cannabis use disorders remain the most common illicit drug use disorder and options for treatment remain limited. Compared to other abusable substances, there has been little investigation of pharmacotherapies for cannabis dependence and no effective pharmacotherapy for cannabis dependence has been developed yet. As such, the development of effective cannabis dependence pharmacotherapy is an important unmet public health need. Lofexidine, an alpha-2 agonist, is effective in treating opioid withdrawal and shows promise as cannabis use disorder pharmacotherapy, though its use may be limited by a cumbersome (thrice daily) dosing regimen. An alpha-2-agonist with a longer half-life, such as guanfacine, may have some of the same benefits as lofexidine at comparable doses, but its easier (once daily) dosing regimen may promote compliance and treatment retention. The purpose of this study is therefore to determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy option for cannabis dependence. This pilot study can also provide the basis for subsequently conducting a larger study aimed at determining efficacy with the appropriate randomized, placebo-controlled design.
Pharmacokinetic studies in patients with CGD have not been performed. The intravenous, intramuscular, and subcutaneous pharmacokinetics of ACTIMMUNE have been investigated in 24 healthy male subjects following single-dose administration of 100 mcg/m2 (twice the recommended dose for CGD and SMO patients). ACTIMMUNE is rapidly cleared after intravenous administration (1.4 Liters/minute) and slowly absorbed after intramuscular or subcutaneous injection. After intramuscular or subcutaneous injection, the apparent fraction of dose absorbed was greater than 89%. The mean elimination half-life after intravenous administration of 100 mcg/m2 in healthy male subjects was 38 minutes. The mean elimination half-lives for intramuscular and subcutaneous dosing with 100 mcg/m2 were 2.9 and 5.9 hours, respectively. Peak plasma concentrations, determined by ELISA, occurred approximately 4 hours (1.5 ng/mL) after intramuscular dosing and 7 hours (0.6 ng/mL) after subcutaneous dosing. Multiple dose subcutaneous pharmacokinetic studies were conducted in 38 healthy male subjects. There was no accumulation of ACTIMMUNE after 12 consecutive daily injections of 100 mcg/m2.

Interferon gamma was not detected in the urine of healthy human volunteers following administration of 100 mcg/m2 of ACTIMMUNE by the intravenous, intramuscular and subcutaneous routes. In vitro perfusion studies utilizing rabbit livers and kidneys demonstrate that these organs are capable of clearing interferon gamma from perfusate.